N/A N=902 Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma
Low Tension Glaucoma
Primary: Change From Baseline in Raw Intraocular Pressure (IOP) by Visit — -3.20; -3.12; -3.22; -3.43 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Normal Tension Glaucoma · Ocular Hypertension
Primary: Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12 — 16.55; -3.37 mmHg
N/A N=44 Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
Normal Tension Glaucoma
Primary: Intraocular Pressure (IOP), Period 1 — 13.72; 13.50; 13.27; 13.36 mmHg — p=0.05
Phase 4 N=97 Steroids After Laser Trabeculoplasty for Glaucoma
Glaucoma
Primary: Intraocular Pressure (IOP) Change — -3.0; -6.2; -5.2 mmHg
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
Phase 2 N=37 COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
Glaucoma
Primary: Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. — -3.73 mmHg — p=<0.0001
Phase 3 N=144 A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma · Open-Angle Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 24.45; 24.38 millimeters of mercury (mmHg)
N/A N=854 Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 19.0; -4.0; 20.0; -5.0 Millimeters of Mercury (mmHg)
N/A N=49 Systemic Glutathione Level in Normal Tension Glaucoma
Normal Tension Glaucoma
Primary: Total Glutathione Levels — 524.02; 586.06 nmol
N/A N=358 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye — -4.5 mmHg
Phase 3 N=240 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure at Week 4 — -6.2; -6.8 mmHg — p=0.0231
Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Phase 2 N=5 Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Adverse Event Rate — 1 Participants
N/A N=419 A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 21.23; 21.38 Millimeters of Mercury (mmHg)
N/A N=933 Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 22.04; 22.07 mm Hg
N/A N=69 Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma
Open Angle Glaucoma
Primary: Intraocular Pressure Reduction — 17.01; 14.29 percentage change
Phase 4 N=111 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
Glaucoma
Primary: Mean Intraocular Pressure (IOP) at 9 AM — 16.3; 18.1 millimeters mercury (mmHg)
N/A N=10,337 A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 20.0; -4.0; 20.0; -4.0 Millimeters of Mercury (mmHg)
Phase 4 N=150 Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
Glaucoma
Primary: Ocular Tolerance — 65; 34 participants — p=< 0.001
N/A N=2,580 A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 20.51; 20.65 Millimeters of Mercury (mmHg)
Phase 1 N=19 CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
Ocular Hypertension · Open Angle Glaucoma
Primary: Ocular Treatment Emergent Adverse Events — 9; 7; 9; 1 Number of Treatment-Emergent Events
Phase 4 N=84 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
Glaucoma · Ocular Hypertension · Open-Angle Glaucoma
Primary: Overall Mean Intraocular Pressure (IOP) — 17.45; 17.22 millimeters mercury (mmHg)
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 4 N=263 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye — 16.5; 16.7; 15.7; 16.1 Millimeters of Mercury (mmHg)
N/A N=312 A Study of Bimatoprost 0.01% in the Clinical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale — 7; 36; 10; 50 Patients
Phase 4 N=87 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Phase 2 N=201 Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Primary Open-Angle Glaucoma (POAG) · Ocular Hypertension (OHT)
Primary: Mean Intraocular Pressure (IOP) — -6.4; -6.8; -6.4; -7.1 mm of mercury
Phase 3 N=126 Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye — 22.35; -3.98 Millimeters of Mercury (mmHg)
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
N/A N=387 Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Baseline — 22.0; 22.0 mm Hg